Protein deacetylase

4D pharma Announces Publication of Preclinical Research Showing Single Strain Megasphaera massiliensis improves activity of CAR-T

Retrieved on: 
Tuesday, July 6, 2021
Oncology, Health, Clinical trials, Research, Science, Pharmaceutical, Biotechnology, Computer programming, 4th Dimension, Cross-platform software, Software engineering, Protein deacetylase, Software, 4D, Histone deacetylase

4D pharma identified M. massiliensis MRx1299 using its MicroRx platform and previously showed MRx1299 to have specific histone deacetylase (HDAC) inhibitory activity and be a rare prolific producer of pentanoate.

Key Points: 
  • 4D pharma identified M. massiliensis MRx1299 using its MicroRx platform and previously showed MRx1299 to have specific histone deacetylase (HDAC) inhibitory activity and be a rare prolific producer of pentanoate.
  • Using the MicroRx platform we have now shown we have the potential to improve the efficacies of cell therapies such as CAR-T, commented Dr. Imke Mulder, Research Director, 4D pharma.
  • 4D has developed a proprietary platform, MicroRx, that rationally identifies Live Biotherapeutics based on a deep understanding of function and mechanism.
  • 4D pharma's Live Biotherapeutic products (LBPs) are orally delivered single strains of bacteria that are naturally found in the healthy human gut.

OnKure, Inc. Raises $55 Million Series B Financing

Retrieved on: 
Thursday, March 4, 2021
Biotechnology, Pharmaceutical, Health, Oncology, Histone deacetylase, Protein deacetylase

OnKure, Inc., a privately-held biopharmaceutical company developing best-in-class, targeted oncology therapeutics, today announced that it has raised $55 million in a Series B financing.

Key Points: 
  • OnKure, Inc., a privately-held biopharmaceutical company developing best-in-class, targeted oncology therapeutics, today announced that it has raised $55 million in a Series B financing.
  • Proceeds will be used to advance the Companys next generation histone deacetylase (HDAC) inhibitors further into clinical development and fund a growing pipeline of earlier stage molecules.
  • The financing was led by Acorn Bioventures with participation from additional new investors Cormorant Asset Management, Surveyor Capital (a Citadel company), Samsara BioCapital, Perceptive Advisors and funds and accounts managed by BlackRock.
  • In connection with the financing, Isaac Manke, Ph.D., Partner at Acorn Bioventures, and Andrew Phillips, Ph.D., Managing Director at Cormorant Asset Management, will join the OnKure board of directors.

Shareholder Alert: Robbins LLP Reminds Investors MEI Pharma, Inc. (MEIP) Accused of Misleading Shareholders

Retrieved on: 
Friday, October 23, 2020
Legal, Professional services, Benzimidazoles, Pracinostat, Protein deacetylase, Histone deacetylase

Shareholder rights law firm Robbins LLP reminds investors that a purchaser of MEI Pharma, Inc. (NASDAQ: MEIP) filed a class action complaint against the Company for alleged violations of the Securities Exchange Act of 1934 between August 2, 2017 and July 1, 2020.

Key Points: 
  • Shareholder rights law firm Robbins LLP reminds investors that a purchaser of MEI Pharma, Inc. (NASDAQ: MEIP) filed a class action complaint against the Company for alleged violations of the Securities Exchange Act of 1934 between August 2, 2017 and July 1, 2020.
  • MEI Pharma is a late-stage pharmaceutical company that focuses on the development of various therapies for the treatment of cancer.
  • One of MEI Pharma's drug candidates include Pracinostat, an oral histone deacetylase (HDAC) inhibitor.
  • On this news, MEI Pharma's shares fell 18% to close at $3.49 per share and has yet to recover.

Histone Deacetylase 8, Pipeline Review, H1 2020: Analysis by Indications, Stage of Development, Mechanism of Action & Route of Administration - ResearchAndMarkets.com

Retrieved on: 
Wednesday, January 29, 2020
Biotechnology, Pharmaceutical, Health, Branches of biology, HDAC8, Proteins, Histone deacetylase, Histone, Protein deacetylase, Histone deacetylase inhibitor

The "Histone Deacetylase 8 - Pipeline Review, H1 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Histone Deacetylase 8 - Pipeline Review, H1 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98) - Histone deacetylase 8 is an enzyme encoded by the HDAC8 gene.
  • Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98) pipeline Target constitutes close to 6 molecules.
  • The latest report Histone Deacetylase 8 - Pipeline Review, H1 2020, outlays comprehensive information on the Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

NAD Dependent Protein Deacetylase Sirtuin 1 - Pipeline Review, H2 2019 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, January 21, 2020
Health, Pharmaceutical, Enzymes, Sirtuin 1, Sirtuin, Protein deacetylase, KIAA1967, Sirtuin 3

The "NAD Dependent Protein Deacetylase Sirtuin 1 - Pipeline Review, H2 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "NAD Dependent Protein Deacetylase Sirtuin 1 - Pipeline Review, H2 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • NAD Dependent Protein Deacetylase Sirtuin 1 (SIR2 Like Protein 1 or Sirtuin Type 1 or Regulatory Protein SIR2 Homolog 1 or SIRT1 or EC 3.5.1.)
  • The latest report NAD Dependent Protein Deacetylase Sirtuin 1 - Pipeline Review, H2 2019, outlays comprehensive information on the NAD Dependent Protein Deacetylase Sirtuin 1 (SIR2 Like Protein 1 or Sirtuin Type 1 or Regulatory Protein SIR2 Homolog 1 or SIRT1 or EC 3.5.1.)
  • NAD Dependent Protein Deacetylase Sirtuin 1 (SIR2 Like Protein 1 or Sirtuin Type 1 or Regulatory Protein SIR2 Homolog 1 or SIRT1 or EC 3.5.1.)

Growth of HDAC (Histone Deacetylase) Inhibitors Market to be Impacted by Increasing Awareness About Cancer | Technavio

Retrieved on: 
Friday, October 18, 2019
Biotechnology, Pharmaceutical, Health, Oncology, Antineoplastic drugs, Histone deacetylase inhibitor, Drugs, Histone deacetylase, Clinical medicine, Branches of biology, Hydroxamic acids, Protein deacetylase, Orphan drugs, Romidepsin, Pracinostat

HDAC (histone deacetylase) Inhibitors Market Landscape 2019-2023: Geographic landscape

Key Points: 
  • HDAC (histone deacetylase) Inhibitors Market Landscape 2019-2023: Geographic landscape
    HDAC (histone deacetylase) Inhibitors Market Landscape 2019-2023: RoA
    Register for a free trial today and gain instant access to 10,000+ market research reports.
  • HDAC inhibitors demonstrate promising results in cancer treatments and can induce apoptosis, cell-cycle arrest, and differentiation.
  • As a result, strong research will help in quick launch of these target-specific HDAC molecules and drive the market.
  • This improves the adherence of patients toward treatment regimen, which in turn, will boost the demand for HDAC (histone deacetylase) inhibitors.

Global Abexinostat (Xynomic Pharmaceuticals) Market Report 2019: Sales, Overview & Product Profiles - ResearchAndMarkets.com

Retrieved on: 
Wednesday, June 26, 2019
Pharmaceutical, Health, Oncology, Branches of biology, Chemical compounds, Amino acids, Proteins, Epigenetics, Orphan drugs, Histone deacetylase, Lysine, Pazopanib, Histone, Protein deacetylase, Histone acetylation and deacetylation

HDAC enzymes (also known as lysine deacetylase) cleave acetyl groups from N-acetyl lysine amino acids on a histone.

Key Points: 
  • HDAC enzymes (also known as lysine deacetylase) cleave acetyl groups from N-acetyl lysine amino acids on a histone.
  • As such, the combination of abexinostat with Votrient (pazopanib; Novartis) is intended to prolong the therapeutic effect of Votrient.
  • Therefore, we do not expect abexinostat to be investigated as a monotherapy for the treatment of renal cell carcinoma (RCC).
  • However, based on the ongoing Phase III trial, abexinostat is only expected to launch for the US market, limiting its potential revenue.